INKT — Mink Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $58.30m
- $49.75m
Annual cashflow statement for Mink Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -16.2 | -30.2 | -28 | -22.5 | -10.8 |
| Depreciation | |||||
| Non-Cash Items | 6.17 | 13.6 | 0.236 | 3.59 | 0.554 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.67 | 3.74 | 8.77 | 2.9 | 0.46 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -8.34 | -12.8 | -18.9 | -15.8 | -9.56 |
| Capital Expenditures | -0.095 | -0.249 | -0.25 | -0.074 | — |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.095 | -0.249 | -0.25 | -0.074 | — |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 11.1 | 49.3 | -0.156 | -0.407 | 10.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.39 | 36.2 | -19.3 | -16.3 | 1.21 |